anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the medicine, in particular to oncology, namely to the technology for production of anticancer preparations, and may be used for treating cancer patients. The anticancer vaccine is obtained in the following way. The surgical material is first rinsed by saline solution. Then the homogenate is produced and treated with the filtrate of the culture medium of B. subtilis B-7025. The human embryonic tissue is used as the surgical material for preparing the vaccine upon the check for the infectious agents. The homogenate is incubated with filtrate of the culture medium at a 1:4 ratio. The treatment is performed by the seven-fold subcutaneous injections of the vaccine in theprogressively reduced volume. The overall volume of the vaccine for one course of the treatment is 16 ml. The treatment is repeated 1-5 times with 1-6-month intervals.
This is a master protocol for a Phase 2 platform clinical trial to evaluate host-directed therapeutic candidates (i.e., investigational product, IP) for the treatment of hospitalized participants diagnosed with ARDS. The safety and efficacy of each IP will be studied within its own cohort (IP versus Placebo). All patients will continue to receive standard treatments for ARDS as per the investigator. An individual participant will complete the study in approximately 90 days. The study will include a screening period (\<24 hours from providing informed consent to treatment), in-hospital treatment period with IP/placebo starting on Day 1 through discharge from the hospital, and a follow-up period after discharge from the hospital through the end of study (Day 90 + 2 weeks). Outcome data will be assembled for each patient over time (such as ventilatory status, oxygenation, and survival). Functional status using the WHO Ordinal scale and Karnofsky scale will be collected. Resource utilization will be calculated (length of stay in a critical care setting, days intubated, and survival).

All participants will undergo a series of physical exams, laboratory assessments/biomarker collections, ECG, Chest X-ray or CT scan, and questionnaires through Day 90. Exploratory biomarkers will be evaluated over time to facilitate clinical learning. This record only includes information relevant to the bevacizumab cohort.
Potassium citrate is a citrate salt of potassium. Its molecular formula is K 3C 6H 5O 7• H 2O, and it has the following chemical structure: 

Potassium citrate, USP is a transparent crystals or white, granular powder. It is freely soluble in water and slightly soluble in alcohol.

Potassium citrate extended-release tablets, USP intended for oral administration, each contains 5 mEq (540 mg), 10 mEq (1,080 mg) or 15 mEq (1,620 mg) of potassium citrate, USP as monohydrate. In addition, each tablet contains the following inactive ingredients: carnauba wax and magnesium stearate.

Meets USP Dissolution Test 2
PURPOSE:To obtain the titled promoting agent containing a specific cyclic organic compound, organic compound having an amine salt and/or tert. nitrogen, antifibrinolysin agent, antiplasmin and hydrolytic enzyme. CONSTITUTION:The aimed blood coagulation promoting agent is obtained by containing a compound (e.g. compound expressed by formula II) expressed by formula I (A is residue of cyclic compound; adjacent carboxyl group exists on a same plane), organic compound having an amine salt and/or tert. nitrogen (e.g. alkylamine hydrochloride), antifibrinolysin agent and/or antiplasmin (e.g. abrotinine, soybean trypsin inhibitor, epsilon-aminocapronic acid) and hydrolytic enzyme (e.g. enzyme such as trypsin or thrombin capable of hydrolyzing a bond of Arg with arbitrary amino acid residue and/or a bond of Lys with arbitrary amino acid residue in a peptide chain). The agent is preferably used in collection of serum in blood examination of artificial dialysis patient and thrombosis patient receiving heparin administration.
Hair dye contacts skin, and is heated during hair dyeing, so that benzene organic substances enter blood capillary through scalp, then reach bone marrow along with blood circulation, and repeatedly act on hemopoietic stem cells for a long term to cause malignancy of the hemopoietic stem cells and cause occurrence of leukemia. An expert says that the hair dye causes skin sensibility, because para-phenylene diamine is a necessary coloring agent and an internationally accepted carcinogenic substance. The hair dye relates to the field of hair dye, and is a herba ecliptae hair dye, which not only has good hair dyeing effect, but also has the function of protecting dyed hair. The hair dye consists of 15 to 20 percent of herba ecliptae (1), 20 to 25 percent of balsamine (2), 10 to 15 percent of henna powder (3), 20 to 25 percent of lilac (4), 20 to 25 percent of angelica (5), 20 to 25 percent of rhubarb (6), and 20 to 25 percent of nutgall (7). The hair dye is prepared by a simple method, and coffee is boiled with water and dispensed with drugs to dye hair. The hair dye has the function of protecting the dyed hair. The herba ecliptae, the balsamine, the henna, the lilac, the angelica, the rhubarb and the nutgall have effects of beautifying and hairdressing, and have specific effects of inhibiting dandruff, strengthening hair roots, preventing atrichia, broken hair and premature grey hair, and the like.
The prepn. of aq. solns. of potentiated sulphonamides, based on a cpd. of formula R1CH(R)2 (I)(R1 is H or organic gp.; R is an antibacterially effective sulphonamide bonded via the amino gp.) and a sulphonamide potentiator, and the dry residue of such solns. comprises (a) dissolving (I) and a sulphonamide potentiator in an inert aprotic org. solvent and then removing the solvent and the residue dissolved in water contg. a base in an amt. equimolar to the sulphonamide, or alternatively (a') dissolving (I), a sulphonamide potentiator and opt. a sulphonamide salt corresp. to (I) and the equiv. amt. of a base in water, and (b) evaporation to provide dry residues.
Oxazepam is the first of a chemical series of compounds known as the 3-hydroxybenzodiazepinones. A therapeutic agent providing versatility and flexibility in control of common emotional disturbances, this product exerts prompt action in a wide variety of disorders associated with anxiety, tension, agitation, and irritability, and anxiety associated with depression. In tolerance and toxicity studies on several animal species, this product reveals significantly greater safety factors than related compounds (chlordiazepoxide and diazepam) and manifests a wide separation of effective doses and doses inducing side effects.

Oxazepam capsules contain 10 mg, 15 mg or 30 mg oxazepam. The following inactive ingredients are contained in these capsules: corn starch, croscarmellose sodium, FD&C Red #40, gelatin, hypromellose, lactose (monohydrate), magnesium stearate, methylparaben, propylparaben, sodium lauryl sulfate, titanium dioxide, and other inert ingredients. The 10 mg capsule also contains D&C Red #28. The 15 mg capsule also contains D&C Yellow #10. The 30 mg capsule also contains D&C Red #28 and FD&C Blue #1.

Oxazepam is 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one. A white crystalline powder with a molecular weight of 286.72, its structural formula is as follows:
INTRODUCTION/AIMS: Fatigue is a common and debilitating symptom encountered in the neuromuscular clinic. The 7-item Fatigue Severity Scale (FSS-7) is a Rasch-modified assessment validated in inflammatory neuropathies but not across a typical neuromuscular patient population. The aim of this study was to validate this measure in neuromuscular disorders and to compare between patient sex, age and diagnoses.
METHODS: The modified FSS-7 was mailed to patients recruited from a specialist neuromuscular clinic at the Walton Centre. Responses were subjected to Rasch analysis and descriptive statistics were performed on the Rasch converted data.
RESULTS: The mFSS-7 met the Rasch model expectations with an overall Chi-square probability of 0.4918, a strict unidimensional scale free from differential item functioning (DIF) that satisfied the model with substantial test-retest reliability using Lin's concordance correlation coefficient 0.71 (95% CI 0.63-0.77). A 15.7% ceiling effect was observed in this patient cohort. Post hoc analysis did not show any significant difference in fatigue between sex, age or neuromuscular diagnoses.
DISCUSSION: The self-completed Rasch mFSS-7 showed acceptable test-retest reliability across patients with varied disorders under follow-up in a specialist neuromuscular clinic. The ceiling effect constrains its use for those with the most severe fatigue. Future considerations could include assessment of the benefits of clinical interventions, particularly multidisciplinary team input or dedicated fatigue clinics.
Effective treatment strategies for chronic depression are urgently needed since it is not only a common and particularly disabling disorder, but is also considered treatment resistant by most clinicians. There are only a few studies on chronic depression indicating that traditional interventions are not as effective as in acute, episodic depression. In addition, most of the studies had methodological weaknesses, such as the very short courses of psychotherapy. Usually, chronic depression begins early in life, is often associated with early interpersonal trauma, and results in an even more substantial human capital loss than the late-onset group. Furthermore, it shows a weak response to medication and a high rate of relapse after an initial response. With the present multicentre study, the efficacy of the only specific psychotherapy for chronic depression (Cognitive Behavioural Analysis System of Psychotherapy/CBASP) is compared with a non-specific System of Supportive Psychotherapy/SYSP in early onset chronically depressives. CBASP faired very well in one large trial but has never been directly compared to a non-specific psychotherapeutic control. Another innovative aspect of the study is the use of an extended course of psychotherapy (32 sessions). Primary hypothesis: CBASP is more effective in reducing depressive symptoms than SYSP.

A naturalistic study following up the patients of the trial up to two years after termination of the study treatments is performed in order to investigate the long-term effectiveness of CBASP compared to the System of Supportive Psychotherapy. The primary outcome of this follow-up study is the rate of well-weeks (weeks with no or minimal depression symptoms) during the two years after termination of the study treatments as measured with the Longitudinal Interval Follow-up Evaluation (LIFE) Interview
Eprosartan Mesylate: Limited data are available regarding overdosage. Appropriate symptomatic and supportive therapy should be given if overdosage should occur. There was no mortality in rats and mice receiving oral doses of up to 3000 mg eprosartan/kg and in dogs receiving oral doses of up to 1000 mg eprosartan/kg. 

Hydrochlorothiazide:  The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, and hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.
<P>PROBLEM TO BE SOLVED: To provide a method for optimizing the recipe to laser-ablation corneal treatment.  <P>SOLUTION: A method for optimizing a prescription for laser-ablation corneal treatment includes the steps of receiving a measured correction prescription for a current patient having a classification element associated therewith, the prescription having been measured using wavefront determination. A database of treatment outcomes on a plurality of previously treated patients is accessed, each treated patient outcome having associated therewith at least one classification element and comprising a preoperative wavefront-determined correction prescription and a postoperative visual profile. From the treatment outcomes in the database is calculated an average difference between the preoperative prescription and the postoperative profile for at least some of the previously treated patients having a classification element in common with the current patient. Finally the current patient correction prescription is adjusted commensurate with the calculated average difference to form an optimized prescription.  <P>COPYRIGHT: (C)2003,JPO
A historical control group of patients receiving single antiplatelet therapy but no high-intensity statin treatment will be drawn from previous prospective observation studies. Antiplatelet therapy includes aspirin(100-300mg/day) or Clopidopgrel (75mg/day).
MBCT-Brief includes 8 weekly 1-hour group sessions delivered either via telephone or video teleconferencing. The decision to deliver the intervention either via phone or teleconferencing will be made based on participant preference obtained during the formative focus groups. Telephone delivery of MBCT-Brief only requires a landline, while teleconferencing requires either a smartphone, tablet, or computer with audio and video functionality. During the MBCT-Brief intervention the instructor will lead in-session practice of medication and cognitive therapy exercises, guided inquiry, and assign and review at-home practice exercises. All sessions will be audio-recorded. Participants will be encouraged to practice daily meditation in between group sessions for 20 minutes, 6 days per week. Participants will complete practice logs to document daily meditation practice.
The invention relates to a therapeutic agent for ischemic diseases having little side effects and being capable of administering safely. The effective component of the therapeutic agent for ischemic diseases of the present invention is an extract from inflammatory tissue inoculated with vaccinia virus. An extract from inflammatory tissue inoculated with vaccinia virus. protects a cell against damage by suppressing abnormal depolarization of hippocampal pyramidal neurons during hypoxia and so can delay the time falling into cell death. The characteristic action is not observed for normal pyramidal neurons, but is expressed only in the stage of pathema during hypoxia. Therefore, the substance of the present invention is useful as a drug to treat and prevent ischemic diseases such as cerebral infarction and the like and symptoms accompanying with neuropathy caused by ischemia.
The application discloses methods and compositions for inhibiting functions associated with Interleukin-8 (IL8). The methods and compositions may involve the use of aptamers for binding to IL8 and preventing or reducing association of IL8 with CXCR1, CXCR2, or both. The methods and compositions may include one or more aptamers that bind to an N-terminal domain of IL8. The methods and compositions may include one or more aptamers that bind to a hydrophobic pocket of IL8. The methods and compositions may include one or more aptamers that bind to an N-loop of IL8. The methods and compositions may include one or more aptamers that bind to a GAG binding site of IL8. The application further provides anti-IL8 aptamers for the treatment of ocular diseases or disorders. In some cases, the anti-IL8 aptamers may have a stem-loop secondary structure.
NEW MATERIAL:A compound shown by formula I (R<1> to R<3> are H or alkyl). USE:Useful as a drug, an agricultural chemical and a reagent for preparing pathologic model of stiff-man syndrome. PREPARATION:For example, an amine compound is obtained by reductive amination reaction between a lactol derivative derived from 2-indane and vinylglycinol derivative derived from L-methionine. Then the amino compound is subjected to N-protection with tert. butoxycarbonyl to give an aldehyde derivative shown by formula II. Then this compound is reacted by light irradiation, selectively oxidized to give a ketone derivative shown by formula III. Further, the ketone derivative is treated by oxidation of methanol into carboxylic acid and esterification with diazomethane. Then the resulting substance is oxidized and cleft and hydrolyzed to give a dicarboxylic acid shown by formula IV, which is reduced to give a compound shown by formula V.
1414812 Sustained release medicaments ALZA CORP 19 Sept 1972 [30 Sept 1971 17 Aug 1972] 43369/72 Addition to 1333576 Heading A5B A device which delivers a medicament at a substantially constant rate over a prolonged period of time comprises a sealed container containing a solid medicament and a liquid in which it is sparingly soluble, the container being composed, at least partially, of a material through which the medicament diffuses at a rate slower than that at which it can be dissolved by the liquid and transported to the inner face of the container wall (this being the sole mode of release of medicament). The container material may be one through which the medicament will diffuse or it may be a microporous material, the pores of which are filled with a liquid through which the medicament diffuses. A very wide range of medicaments. liquids and container materials are specified, the latter being chiefly various natural and synthetic polymers. Examples relate to contraceptive implants and intra-uterine devices comprising a hormone, e.g. progesterone, and a liquid e.g. asilicone oil, aqueous polyvinyl pyrrolidone or aqueous carboxymethylcellulose enclosed within a container composed essentially of polyethylene, ethylene/vinyl acetate copolymer or cured silicone; cortisone and aqueous methyl cellulose in an ethylene/vinyl acetate elastomer container; phenagocine HCL and water in a PVC, ethylene/vinyl acetate copolymer or radiation cross-linked poly(cis-1, 4-polyisoprene); pilocarpine and an unspecified liquid in ethylene/vinyl acetate copolymer (ocular insert) and various shaped devices (polyethylene "band", polyethylene heart valve and polyamide suture) containing unspecified medicaments.
Children are the future to our society. The first thousand days of life, starting from conception till one's second birthday is a critical period of cognitive and physical development. It is the most sensitive period where brain development is most receptive to positive nutrition. Any form of malnutrition, especially during this golden time frame, can lead to irreversible effects to growth, health, education and future career attainment to our potential leaders, which in turn can be a barrier to human development.

The CoVID outbreak is a unique period in recent human history where drastic public health measures such as MCO for an extended period of time has to be implemented nation-wide. These measures have untold severe consequences on the food security of the vulnerable urban group, in particular the young children whose brains require diverse micronutrients to support the rapid growth. These micronutrients can only be obtained from a daily diet that is equally diverse, especially from fresh vegetables and fruits which will be short in supplies. These perishable food items are not usually included in food aids, thus the child may have to subsist on staple-rich diet which are energy-dense but nutrient-poor. These dietary practices are associated with negative health outcomes. Thus by monitoring dietary diversity of the children, we hope to better inform food aid organisations to consider the inclusion of healthier food options to prevent micronutrient deficiencies.
PURPOSE: This methodological study describes a technique for extracting information from de-identified electronic health records (EHRs) to identify occurrences of permanent unilateral hearing loss (UHL) and associated educational comorbidities.
METHOD: This was an exploratory methodological study utilizing approximately 3.3 million de-identified medical records. Structured and unstructured data were extracted using both automated and manual methods. When both methods were available, positive and negative predictive values were calculated to evaluate the utility of using automated methods.
RESULTS: We defined a cohort of 471 records that met our criteria of school-age children with permanent UHL and no additional significant disabilities/diagnoses. Fifty-one percent of the children reflected in this cohort had indicators of adverse educational progress, defined as documentation of receiving educational services, speech-language therapy, and/or parental/teacher concern, with 12% of records reflecting overlapping services/concerns. Negative predictive values were generally high and positive predictive values were generally low, suggesting automated searches are useful for excluding factors of interest, but not finding them.
CONCLUSIONS: This study demonstrates the feasibility of using EHRs in examining UHL in school-age children. By restricting our cohort to individuals who were seen in audiology clinic, we were able to capture variables such as educational difficulty that are not routinely ascertained in medical contexts. The proportion of children in this cohort demonstrating a marker of adverse educational progress is consistent with numerous prior observational studies, thus providing validity to this ascertainment approach. We describe challenges encountered in creating this cohort and detail our hybrid approach to ascertaining key variables accurately.
In-person baseline surveys (using paper and pen surveys) before the random assignment to HRVB waitlist group. After the baseline data collection, for two weeks, they will be provided educational material regarding education materials and coping with stress and they will be encouraged to read them during the two weeks. At the end of the two-week period, participants will be scheduled for a final in-person session including T2 survey and HRV assessment. They will be also provided HRVB training session at T2.
The study will be a prospective randomized-controlled trial comparing LRTI and mini tightrope suspensionplasty for the surgical treatment of basilar thumb arthritis. Patients meeting operative criteria who present to Level One Orthopaedics at Orlando Health will be consented for study participation. Subsequently, consented patients will be randomized into one of three treatment arms: LRTI, suspensionplasty with one-suture construct and suspensionplasty with two-suture construct. The patient will be blinded prior to the procedure; however, the performing surgeon will not be able to be blinded. The patient will become un-blinded postoperatively when the performing surgeon informs them which method was used. The investigators will then follow the patients for 5 years to assess the primary and secondary outcomes (see below) and analyze the data with an intention-to-treat method before publishing the conclusions. Follow-up visits will occur at two weeks, one month, three months, six months, one year, and five years. Outcome measures will incorporate subjective and objective measures and will include the SF-36 and Disabilities of Arm, Shoulder \& Hand (DASH) questionnaires, pinch/grip strength, visual analog pain scale, patient satisfaction and postoperative complications.